Blocking a signaling pathway in certain white blood cells may prevent blood clots from obstructing blood flow in the pulmonary arteries — the cause of chronic thromboembolic pulmonary hypertension (CTEPH). That’s according to a new study that investigated whether a certain immune signaling pathway in the body plays a…
News
Nine members of the pulmonary hypertension (PH) community have received awards for their support of the Pulmonary Hypertension Association (PHA). At the PHA 2026 International PH Conference and Scientific Sessions in Dallas, the community gathered to celebrate the recipients of this year’s member awards. “The Outstanding…
Oxiwear‘s wearable medical device, which continuously tracks oxygen levels in people with pulmonary hypertension (PH) and other heart or lung conditions, will now be covered by Medicare and certain private insurance providers in the U.S., the company announced. The…
Enrollment is complete in the Phase 2 APEX trial of TX45, Tectonic Therapeutic‘s experimental drug for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF), the company reports. “Reaching full enrollment in our APEX Phase 2 clinical trial represents a critical milestone for our TX45 clinical development program…
A gene called NDRG1 may help drive blood vessel remodeling seen in chronic thromboembolic pulmonary hypertension (CTEPH) by shifting smooth muscle cells toward a scar-forming state, a study found. “NDRG1 and related key gene axes may serve as potential therapeutic targets for CTEPH,” researchers wrote. The study, “Single-cell transcriptomics…
While both Winrevair (sotatercept) and prostacyclin therapies are used to treat pulmonary arterial hypertension (PAH), a new study shows the two treatments appear to affect blood flow differently among PAH patients. When people with this rare type of pulmonary hypertension started prostacyclin treatment, resistance to blood flow in the…
Low blood levels of several oxygen‐sensing molecules are found in people with pulmonary arterial hypertension (PAH), and testing for them may be a useful noninvasive tool for helping make a PAH diagnosis, according to a new study. Specifically, levels of a protein subunit known as HIF-1alpha showed strong…
Subtle liver problems may contribute to the development of pulmonary arterial hypertension (PAH), suggesting complex communication between the lungs and liver along a so-called lung-liver axis, according to a study. Some people with PAH but no known liver disease showed signs of mild liver dysfunction, enhanced lung-related inflammatory processes,…
Corsair Pharma‘s experimental skin-worn patch designed to deliver treprostinil, an approved treatment for pulmonary arterial hypertension (PAH), appears to be working as intended, according to newly announced data from an early clinical trial in healthy volunteers. “These data support the potential of our transdermal [through-the-skin] platform as a…
Higher TAGLN2 gene activity may contribute to the development of pulmonary arterial hypertension (PAH), according to a new study. Using genetic analyses and experiments in animals, researchers identified two specific DNA sites that influenced TAGLN2 expression (activity) and PAH risk. These are two sites where a chemical mark called…
Risk factors for pulmonary hypertension (PH) in people receiving maintenance hemodialysis, a blood-filtering treatment used when kidney function is severely reduced, appear to change with age, according to a single-center study in China. Diabetes was a risk factor for PH in patients 60 or older. In younger patients, PH…
Note: This story was updated May 28, 2026, to clarify the indications for which Cereno Scientific’s experimental therapies are being developed. The company is advancing CS1 as a potential treatment for pulmonary arterial hypertension. The first participant has been dosed in a clinical trial testing the pharmacological properties of…
